MD Semaglutide

BIBLIOGRAPHY / PRIMARY SOURCES

References

Every quantitative claim on this site cites one of the studies below. Primary literature only — Phase 3 trials, meta-analyses, and the relevant pharmacology and safety reviews.

Back to research View FAQ
CITATIONS 20
JOURNALS 9
YEAR RANGE 2016–2025
OPEN ACCESS 7
Abstract editorial pattern suggesting a journal reference index

How to read this list

References are numbered in the order they first appear across the site. The full citation, DOI (where available), and a link to PubMed, PubMed Central, or the publishing journal are given for each. All cited trials and reviews are open to inspection on their respective publisher sites; readers are encouraged to consult the primary literature rather than summaries.

Bibliography

  1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016. [link] doi:10.1056/NEJMoa1607141 · PMID 27633186
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. [link] doi:10.1056/NEJMoa2032183
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023; 389:2221–2232. [link] doi:10.1056/NEJMoa2307563
  4. Perkovic V, Tuttle KR, Rossing P, et al. (FLOW Trial Steering Committee and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024. [link] doi:10.1056/NEJMoa2403347
  5. Husain M, Birkenfeld AL, Donsmark M, et al. (PIONEER 6 Investigators). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2019. [link] doi:10.1056/NEJMoa1901118 · PMID 31185157
  6. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018. [link] doi:10.1016/S2213-8587(18)30024-X
  7. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022; 327(2):138–150. [link] doi:10.1001/jama.2021.23619 · PMID 35015037
  8. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022; 28:2083–2091. [link] doi:10.1038/s41591-022-02026-4
  9. Weghuber D, Barrett T, Barrientos-Pérez M, et al. (STEP TEENS Investigators). Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022; 387:2245–2257. [link] doi:10.1056/NEJMoa2208601
  10. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. (STEP-HFpEF Trial Committees and Investigators). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023. [link] doi:10.1056/NEJMoa2306963
  11. Sanyal AJ, Newsome PN, et al. (ESSENCE Trial Investigators). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. New England Journal of Medicine. 2025 (published June 5, 2025). [link] doi:10.1056/NEJMoa2413258
  12. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025; 82(4):395–405. [link] doi:10.1001/jamapsychiatry.2024.4789 · PMID 39937469
  13. Andersen A, Knop FK, Vilsbøll T. Semaglutide for type 2 diabetes (review). Drugs (open-access PMC). 2020. [link] PMC7450779
  14. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022; 24(8):1553–1564. [link] doi:10.1111/dom.14725 · PMC9542252
  15. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. 2024. [link] doi:10.1038/s41591-024-02996-7 · PMC11271387
  16. Mahaffey KW, Tuttle KR, Rossing P, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European Heart Journal. 2024. [link] doi:10.1093/eurheartj/ehae613 · PMC11931213
  17. Smith J et al. Semaglutide — Drug Information. StatPearls (NCBI Bookshelf). 2024. [link] NBK603723
  18. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. International Journal of Molecular Sciences. 2024; 25(8):4346. [link] doi:10.3390/ijms25084346
  19. Smits MM, Van Raalte DH. Safety of Semaglutide. Frontiers in Endocrinology. 2021. [link] PMC8294388
  20. Aroda VR, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. The Lancet. 2023. [link] doi:10.1016/S0140-6736(23)01127-3